[8-K] Maze Therapeutics, Inc. Reports Material Event
Maze Therapeutics, Inc. reported that on August 12, 2025 it issued a press release reporting its financial results for the second quarter ended June 30, 2025. The filing states the full text of that press release is furnished as Exhibit 99.1 to this Current Report. The Company notes that the information in Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or subject to certain liabilities under the Securities Act. The Form 8-K identifies the registrant as Maze Therapeutics, Inc., lists its Nasdaq trading symbol MAZE, shows Delaware as its jurisdiction of incorporation, and indicates it is an emerging growth company.
Maze Therapeutics, Inc. ha comunicato che il 12 agosto 2025 ha diffuso un comunicato stampa con i risultati finanziari del secondo trimestre chiuso al 30 giugno 2025. Il deposito dichiara che il testo integrale di quel comunicato è fornito come Exhibit 99.1 nel presente Current Report. La Società precisa che le informazioni contenute nell'Item 2.02, compreso l'Exhibit 99.1, sono furnished e non devono essere considerate "filed" ai sensi della Sezione 18 dell'Exchange Act né soggette ad alcune responsabilità previste dal Securities Act. Il modulo 8-K identifica il registrant come Maze Therapeutics, Inc., indica il simbolo Nasdaq MAZE, riporta il Delaware quale giurisdizione di costituzione e segnala che si tratta di un'emerging growth company.
Maze Therapeutics, Inc. informó que el 12 de agosto de 2025 emitió un comunicado de prensa con sus resultados financieros del segundo trimestre cerrado el 30 de junio de 2025. El documento indica que el texto completo de ese comunicado se suministra como Exhibit 99.1 en este Current Report. La Compañía aclara que la información en el Item 2.02, incluido el Exhibit 99.1, está furnished y no debe considerarse "filed" a efectos de la Sección 18 del Exchange Act ni estar sujeta a determinadas responsabilidades conforme al Securities Act. El Formulario 8-K identifica al registrant como Maze Therapeutics, Inc., señala su símbolo en Nasdaq MAZE, muestra a Delaware como jurisdicción de constitución e indica que es una emerging growth company.
Maze Therapeutics, Inc.는 2025년 8월 12일 2025년 6월 30일로 종료된 2분기 재무실적을 보고하는 보도자료를 발표했다고 보고했습니다. 제출서류에는 해당 보도자료 전문이 본 Current Report의 Exhibit 99.1로 제공된다고 명시되어 있습니다. 회사는 항목 2.02의 정보(Exhibit 99.1 포함)가 furnished로 제공되며 "filed"로 간주되지 않아 Exchange Act의 섹션 18 적용 대상이 아니고 Securities Act에 따른 일부 책임의 대상이 되지 않는다고 밝혔습니다. Form 8-K에는 등록인 명칭이 Maze Therapeutics, Inc.로 기재되어 있고, 나스닥 거래 기호 MAZE, 델라웨어를 설립 관할지로 표시하며 emerging growth company임을 명시합니다.
Maze Therapeutics, Inc. a déclaré que le 12 août 2025 elle a publié un communiqué de presse rendant compte de ses résultats financiers pour le deuxième trimestre clos le 30 juin 2025. Le dépôt indique que le texte intégral de ce communiqué est fourni en tant que Exhibit 99.1 dans ce Current Report. La Société précise que les informations de l'Item 2.02, y compris l'Exhibit 99.1, sont furnished et ne doivent pas être considérées comme "filed" aux fins de la Section 18 de l'Exchange Act, ni soumises à certaines responsabilités prévues par le Securities Act. Le formulaire 8-K identifie l'enregistrant comme Maze Therapeutics, Inc., indique le symbole Nasdaq MAZE, mentionne le Delaware comme juridiction d'incorporation et précise qu'il s'agit d'une emerging growth company.
Maze Therapeutics, Inc. meldete, dass es am 12. August 2025 eine Pressemitteilung zu seinen Finanzergebnissen für das am 30. Juni 2025 beendete zweite Quartal veröffentlicht hat. Die Einreichung besagt, dass der vollständige Text dieser Pressemitteilung als Exhibit 99.1 in diesem Current Report bereitgestellt wird. Das Unternehmen weist darauf hin, dass die Angaben in Punkt 2.02, einschließlich Exhibit 99.1, furnished sind und nicht als "filed" im Sinne von Section 18 des Exchange Act gelten oder bestimmten Haftungen nach dem Securities Act unterliegen. Das Formular 8-K nennt den Registranten Maze Therapeutics, Inc., führt das Nasdaq-Tickersymbol MAZE auf, nennt Delaware als Gründungsjurisdiktion und gibt an, dass es sich um ein emerging growth company handelt.
- Press release reporting Q2 2025 results was furnished as Exhibit 99.1, providing investors with a designated disclosure mechanism.
- Company details and listing are clear: registrant identified, Nasdaq ticker MAZE, and emerging growth company status indicated.
- No financial figures or tables are included in the body of this Form 8-K; the filing references a press release but does not present the results directly.
- The press release is explicitly furnished, not filed, which the company notes limits certain statutory liabilities and incorporation by reference.
Insights
TL;DR: Routine Form 8-K furnishing a Q2 2025 earnings press release; the filing contains no financial figures and the release is furnished, not filed.
The filing explicitly states that Maze issued a press release on August 12, 2025 reporting results for the quarter ended June 30, 2025 and that the press release is furnished as Exhibit 99.1. The 8-K does not include numerical results or tables within the body of the report. The company also clarifies the press release is not "filed" for Section 18 purposes, which is a standard legal statement minimizing certain post-filing liabilities. For investors seeking substantive financial metrics, this filing points to an external exhibit rather than providing the figures directly in the 8-K text.
TL;DR: Administrative disclosure consistent with standard practice; exhibits furnished rather than filed, and the report is signed by the company secretary.
The 8-K documents a routine disclosure event: a press release reporting quarterly results furnished as an exhibit. The form confirms corporate details (jurisdiction, Nasdaq listing under MAZE) and indicates the company is an emerging growth company. The signature block shows the report was executed by Courtney Phillips, General Counsel and Corporate Secretary, on August 12, 2025. The explicit statement that the exhibit is furnished and not filed is a common governance/legal provision and limits incorporation-by-reference and certain liabilities.
Maze Therapeutics, Inc. ha comunicato che il 12 agosto 2025 ha diffuso un comunicato stampa con i risultati finanziari del secondo trimestre chiuso al 30 giugno 2025. Il deposito dichiara che il testo integrale di quel comunicato è fornito come Exhibit 99.1 nel presente Current Report. La Società precisa che le informazioni contenute nell'Item 2.02, compreso l'Exhibit 99.1, sono furnished e non devono essere considerate "filed" ai sensi della Sezione 18 dell'Exchange Act né soggette ad alcune responsabilità previste dal Securities Act. Il modulo 8-K identifica il registrant come Maze Therapeutics, Inc., indica il simbolo Nasdaq MAZE, riporta il Delaware quale giurisdizione di costituzione e segnala che si tratta di un'emerging growth company.
Maze Therapeutics, Inc. informó que el 12 de agosto de 2025 emitió un comunicado de prensa con sus resultados financieros del segundo trimestre cerrado el 30 de junio de 2025. El documento indica que el texto completo de ese comunicado se suministra como Exhibit 99.1 en este Current Report. La Compañía aclara que la información en el Item 2.02, incluido el Exhibit 99.1, está furnished y no debe considerarse "filed" a efectos de la Sección 18 del Exchange Act ni estar sujeta a determinadas responsabilidades conforme al Securities Act. El Formulario 8-K identifica al registrant como Maze Therapeutics, Inc., señala su símbolo en Nasdaq MAZE, muestra a Delaware como jurisdicción de constitución e indica que es una emerging growth company.
Maze Therapeutics, Inc.는 2025년 8월 12일 2025년 6월 30일로 종료된 2분기 재무실적을 보고하는 보도자료를 발표했다고 보고했습니다. 제출서류에는 해당 보도자료 전문이 본 Current Report의 Exhibit 99.1로 제공된다고 명시되어 있습니다. 회사는 항목 2.02의 정보(Exhibit 99.1 포함)가 furnished로 제공되며 "filed"로 간주되지 않아 Exchange Act의 섹션 18 적용 대상이 아니고 Securities Act에 따른 일부 책임의 대상이 되지 않는다고 밝혔습니다. Form 8-K에는 등록인 명칭이 Maze Therapeutics, Inc.로 기재되어 있고, 나스닥 거래 기호 MAZE, 델라웨어를 설립 관할지로 표시하며 emerging growth company임을 명시합니다.
Maze Therapeutics, Inc. a déclaré que le 12 août 2025 elle a publié un communiqué de presse rendant compte de ses résultats financiers pour le deuxième trimestre clos le 30 juin 2025. Le dépôt indique que le texte intégral de ce communiqué est fourni en tant que Exhibit 99.1 dans ce Current Report. La Société précise que les informations de l'Item 2.02, y compris l'Exhibit 99.1, sont furnished et ne doivent pas être considérées comme "filed" aux fins de la Section 18 de l'Exchange Act, ni soumises à certaines responsabilités prévues par le Securities Act. Le formulaire 8-K identifie l'enregistrant comme Maze Therapeutics, Inc., indique le symbole Nasdaq MAZE, mentionne le Delaware comme juridiction d'incorporation et précise qu'il s'agit d'une emerging growth company.
Maze Therapeutics, Inc. meldete, dass es am 12. August 2025 eine Pressemitteilung zu seinen Finanzergebnissen für das am 30. Juni 2025 beendete zweite Quartal veröffentlicht hat. Die Einreichung besagt, dass der vollständige Text dieser Pressemitteilung als Exhibit 99.1 in diesem Current Report bereitgestellt wird. Das Unternehmen weist darauf hin, dass die Angaben in Punkt 2.02, einschließlich Exhibit 99.1, furnished sind und nicht als "filed" im Sinne von Section 18 des Exchange Act gelten oder bestimmten Haftungen nach dem Securities Act unterliegen. Das Formular 8-K nennt den Registranten Maze Therapeutics, Inc., führt das Nasdaq-Tickersymbol MAZE auf, nennt Delaware als Gründungsjurisdiktion und gibt an, dass es sich um ein emerging growth company handelt.
FAQ
What did Maze Therapeutics (MAZE) disclose in this Form 8-K?
Does this Form 8-K include the company’s Q2 2025 financial numbers?
Is the press release considered "filed" under the Securities Exchange Act?
What is Maze’s ticker and corporate jurisdiction listed in the filing?
Who signed the Form 8-K for Maze Therapeutics?
